AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Large ribosomal subunit protein eL13

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P26373

UPID:

RL13_HUMAN

Alternative names:

60S ribosomal protein L13; Breast basic conserved protein 1

Alternative UPACC:

P26373; B4DLX3; F5H1S2; Q3KQT8; Q567Q8; Q9BPX0

Background:

The Large ribosomal subunit protein eL13, also known as 60S ribosomal protein L13 and Breast basic conserved protein 1, plays a pivotal role in protein synthesis. It is a component of the ribosome, facilitating the synthesis of proteins by translating mRNA messages into polypeptide chains. This process involves the selection of cognate tRNA molecules and the catalysis of peptide bonds in the large subunit's peptidyl transferase center. Additionally, eL13 is crucial for bone development.

Therapeutic significance:

Given its essential role in protein synthesis and bone development, Large ribosomal subunit protein eL13's dysfunction is linked to Spondyloepimetaphyseal dysplasia, Isidor-Toutain type, a bone disease characterized by growth deficiency and skeletal abnormalities. Understanding the role of Large ribosomal subunit protein eL13 could open doors to potential therapeutic strategies for this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.